Fennec Pharmaceuticals:
Hearing Loss Prevention
The Testicular Cancer Awareness Foundation is proud to collaborate with Fennec Pharmaceuticals to help raise awareness among testicular cancer patients about the risk of ototoxicity and the potential benefits of PEDMARK.
Together, we are working to ensure patients and healthcare providers have access to critical information that supports informed decision-making and preserves quality of life during & after treatment.
Ototoxicity due to Cisplatin
Cisplatin is a platinum-based therapy that is widely used and highly effective for testicular cancer. However, one of the side effects is ototoxicity or hearing loss. Therapies like Cisplatin damage the sensory hair cells of the inner ear that communicate to the nervous system and auditory cortex of the brain. This has a profound impact on quality of life after treatment.
Testicular Cancer Awareness Foundation has partnered with Fennec Pharmaceuticals, a biotechnology company dedicated to work in the Neuro-ototoxicity space for patients with testicular cancer who are treated with cisplatin to reduce the risk of hearing loss.
Fennec’s mission
Fennec Pharmaceuticals is dedicated to reducing the risk of ototoxicity—hearing loss caused by chemotherapy—in patients with solid tumors treated with cisplatin, a highly effective but potentially damaging chemotherapy commonly used to treat testicular cancer.
Preserving hearing isn’t just a medical goal—it’s a deeply human one. Hearing shapes how we connect, communicate, and experience the world. For those facing testicular cancer, hearing loss can lead to long-term effects on relationships, work, mental health, and overall well-being.
By minimizing this risk, Fennec is helping patients maintain their independence, dignity, and sense of normalcy during an incredibly challenging time. It’s a powerful reminder that survivorship is not just about quantity of life, but quality of life.
Interested in PEDMARK?
Fennec Hears Can Help You Navigate Your Options
Fennec HEARS is designed to ensure you and your family have the support you need—when you need it most. As a single-source program, Fennec HEARS provides both financial assistance and product access support, helping to make PEDMARK more accessible to eligible patients throughout their treatment journey.
Fennec Pharmaceuticals has developed PEDMARK, the first and only FDA-approved sodium thiosulfate (STS) formulation specifically designed to reduce the risk of cisplatin-induced ototoxicity. No generic version of PEDMARK is approved, and it cannot be substituted with any other STS formulation. For more information, talk to your doctor and visit www.pedmark.com.
PEDMARK is FDA-approved for use in adolescent and young adult oncology patients and is recommended by the National Comprehensive Cancer Network (NCCN) guidelines for those ages 15-39. However, it can also be administered to older adults.
Fennec Pharmaceuticals is committed to ensuring that the cost of PEDMARK does not prevent eligible patients from accessing the treatment they need.
To help with this, Fennec has developed a Patient Assistance Program that offers support to individuals without insurance coverage.
To find out if you qualify for assistance, contact a Fennec HEARS Care Coordinator at 1-833-7PEDMARK (1-833-773-3627) or complete the enrollment form.